{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:23:26Z","timestamp":1791638606083,"version":"4.3.4"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006464","name":"Birla Institute of Technology and Science, Pilani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006464","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lfs.2024.123089","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T02:38:55Z","timestamp":1727750335000},"page":"123089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens"],"prefix":"10.1016","volume":"357","author":[{"given":"Jayant Singh","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivangi","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Taliyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lfs.2024.123089_bb0005","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-8017","article-title":"A narrative review of research progress on drug therapies for glioblastoma multiforme","volume":"9","author":"Zheng","year":"2021","journal-title":"Ann Transl Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0010","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.lfs.2024.123089_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"GBM treatment overview","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1215\/15228517-2007-016","article-title":"Incidence of gliomas by anatomic location","volume":"9","author":"Larjavaara","year":"2007","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.661123","article-title":"Efficacy of location-based features for survival prediction of patients with glioblastoma depending on resection status","volume":"11","author":"Soltani","year":"2021","journal-title":"Front. Oncol."},{"issue":"27","key":"10.1016\/j.lfs.2024.123089_bb0030","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.2174\/0929867324666170516123206","article-title":"Glioblastoma multiforme, diagnosis and treatment; recent literature review","volume":"24","author":"Batash","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.lfs.2024.123089_bb0035","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2024.123089_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.574012","article-title":"A review of newly diagnosed glioblastoma","volume":"10","author":"Oronsky","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0045","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fonc.2019.00963","article-title":"Glioblastoma multiforme: an overview of emerging therapeutic targets","volume":"9","author":"Taylor","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0050","series-title":"Advances in Biology and Treatment of Glioblastoma","first-page":"19","article-title":"Molecular pathology of glioblastoma-an update","author":"Santosh","year":"2017"},{"issue":"4","key":"10.1016\/j.lfs.2024.123089_bb0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/labinvest.3700070","article-title":"Vaso-occlusive and prothrombotic mechanisms associated with tumour hypoxia, necrosis, and accelerated growth in glioblastoma","volume":"84","author":"Brat","year":"2004","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","article-title":"Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies","volume":"61","author":"Agnihotri","year":"2013","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85841","article-title":"Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype","volume":"1","author":"Gabrusiewicz","year":"2016","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0070","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nri3265","article-title":"The anatomical and cellular basis of immune surveillance in the central nervous system","volume":"12","author":"Ransohoff","year":"2012","journal-title":"Nat Rev Immunol [Internet]."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2045-8118-8-4","article-title":"Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle","volume":"8","author":"Engelhardt","year":"2011","journal-title":"Fluids Barriers CNS [Internet]"},{"issue":"10","key":"10.1016\/j.lfs.2024.123089_bb0080","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.it.2015.08.002","article-title":"Immune surveillance of the CNS following infection and injury","volume":"36","author":"Russo","year":"2015","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.lfs.2024.123089_bb0085","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nn.3161","article-title":"Immune surveillance in the central nervous system","volume":"15","author":"Ousman","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2024.123089_bb0090","first-page":"S232","article-title":"The role of inflammation in CNS disease and injury","volume":"147","author":"Lucas","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123089_bb0095","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1172\/JCI58644","article-title":"Innate immunity in the central nervous system","volume":"122","author":"Ransohoff","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1017\/S1740925X12000063","article-title":"Functions of microglia in the central nervous system\u2013beyond the immune response","volume":"7","author":"Wake","year":"2011","journal-title":"Neuron Glia Biol."},{"key":"10.1016\/j.lfs.2024.123089_bb0105","first-page":"1","article-title":"The concept of neuroglia","author":"Verkhratsky","year":"2019","journal-title":"Neuroglia Neurodegener. Dis."},{"key":"10.1016\/j.lfs.2024.123089_bb0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0115","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020560","article-title":"Microglia in health and disease","volume":"8","author":"Ransohoff","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.lfs.2024.123089_bb0120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature17630","article-title":"TAM receptors regulate multiple features of microglial physiology","volume":"532","author":"Fourgeaud","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.lfs.2024.123089_bb0125","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41583-018-0057-5","article-title":"Microglial signatures and their role in health and disease","volume":"19","author":"Butovsky","year":"2018","journal-title":"Nat Rev Neurosci [Internet]"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/jnc.15327","article-title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","volume":"158","author":"Butler","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2024.123089_bb0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2024.123089_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fncel.2018.00329","article-title":"Role of microglia TLRs in neurodegeneration","volume":"12","author":"Fiebich","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.lfs.2024.123089_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.conb.2015.09.003","article-title":"Fine-tuning of type I IFN-\u01b4 signalling in microglia\u2014implications for homeostasis, CNS autoimmunity and interferonopathies","volume":"36","author":"Goldmann","year":"2016","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.lfs.2024.123089_bb0150","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3389\/fimmu.2019.01314","article-title":"The potential of astrocytes as immune modulators in brain tumours","volume":"10","author":"Priego","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123089_bb0155","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte crosstalk in CNS inflammation","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"issue":"5979","key":"10.1016\/j.lfs.2024.123089_bb0160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/310688a0","article-title":"Inducible expression of H\u20132 and Ia antigens on brain cells","volume":"310","author":"Wong","year":"1984","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lfs.2024.123089_bb0165","first-page":"789","article-title":"Intrathecal application of interferon-gamma. Progressive appearance of MHC antigens within the rat nervous system","volume":"137","author":"Vass","year":"1990","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0170","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2016.06.006","article-title":"Astrocytes: key regulators of neuroinflammation","volume":"37","author":"Colombo","year":"2016","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0175","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/glia.20117","article-title":"Differential activation of astrocytes by innate and adaptive immune stimuli","volume":"49","author":"Carpentier","year":"2005","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/glia.1107","article-title":"Immune function of astrocytes","volume":"36","author":"Dong","year":"2001","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0185","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","article-title":"Astrocytes are active players in cerebral innate immunity","volume":"28","author":"Farina","year":"2007","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.immuni.2021.01.013","article-title":"Astrocyte-immune cell interactions in physiology and pathology","volume":"54","author":"Han","year":"2021","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0195","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202715","article-title":"Functional immune cell\u2013astrocyte interactions","volume":"218","author":"Sanmarco","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2024.123089_bb0205","series-title":"Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy","first-page":"653","article-title":"The immune response to glioblastoma: overview and focus on checkpoint blockade","author":"Johanns","year":"2018"},{"issue":"6024","key":"10.1016\/j.lfs.2024.123089_bb0210","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.lfs.2024.123089_bb0220","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","article-title":"Metabolic regulation of the cancer-immunity cycle","volume":"42","author":"Patterson","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585616","article-title":"Glioblastoma immune landscape and the potential of new immunotherapies","volume":"11","author":"Daubon","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.lfs.2024.123089_bb0230","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41416-018-0258-8","article-title":"Harnessing the immune system in glioblastoma","volume":"119","author":"Brown","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy, Asthma Clin. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0240","first-page":"1","article-title":"Molecular biology of the HLA class I and class II genes","volume":"3","author":"Wake","year":"1986","journal-title":"Mol. Biol. Med."},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0245","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0250","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-3146-6_5","article-title":"Mechanisms of immune evasion by gliomas","volume":"53\u201376","author":"Rolle","year":"2012","journal-title":"Glioma"},{"issue":"2016","key":"10.1016\/j.lfs.2024.123089_bb0255","first-page":"11","article-title":"Immune evasion strategies of glioblastoma","volume":"3","author":"Razavi","year":"2016","journal-title":"Front. Surg."},{"issue":"14","key":"10.1016\/j.lfs.2024.123089_bb0260","first-page":"10","article-title":"Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and-independent adoptive immunotherapies","volume":"5","author":"Wang","year":"2020","journal-title":"Ann. Blood"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0265","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/labinvest.3700233","article-title":"Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain","volume":"85","author":"Zagzag","year":"2005","journal-title":"Lab. Invest."},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0270","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/ph14030236","article-title":"Regulation of MHC I molecules in glioblastoma cells and the sensitizing of NK cells","volume":"14","author":"Burster","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0275","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current research in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.lfs.2024.123089_bb0285","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.lfs.2024.123089_bb0295","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.123089_bb0300","series-title":"CTLA-4 on Regulatory T Cells-Regulation of Local Immune Response in Lung Cancer","author":"Osinska","year":"2015"},{"key":"10.1016\/j.lfs.2024.123089_bb0305","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2024.123089_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0315","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2013.12.004","article-title":"The role of regulatory T-cells in glioma immunology","volume":"119","author":"Ooi","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","article-title":"Regulatory T cells in the tumour microenvironment: new mechanisms, potential therapeutic strategies, and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.lfs.2024.123089_bb0325","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lfs.2024.123089_bb0330","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2011.03.018","article-title":"Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation","volume":"34","author":"Chaudhry","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2024.123089_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.786728","article-title":"TGF-\u03b2 signaling and resistance to cancer therapy","volume":"9","author":"Zhang","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.lfs.2024.123089_bb0340","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3389\/fonc.2021.693517","article-title":"Tumor-associated macrophages: a potential target for cancer therapy","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0345","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0355","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/486912","article-title":"Tumor-associated macrophages in glioma: friend or foe?","volume":"2013","author":"Kennedy","year":"2013","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.lfs.2024.123089_bb0360","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/cancers14051319","article-title":"Tumor-associated macrophages in gliomas\u2014basic insights and treatment opportunities","volume":"14","author":"Andersen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.123089_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.706286","article-title":"Tumor-associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor\u2014glioma therapy?","volume":"9","author":"Tong","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.lfs.2024.123089_bb0370","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor-associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2024.123089_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0380","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/cells10010018","article-title":"Myeloid cells in glioblastoma microenvironment","volume":"10","author":"de Leo","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0385","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0390","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0213-9626(11)70015-4","article-title":"Myeloid-derived suppressor cells (MDSC): another player in the orchestra","volume":"30","author":"Gimeno","year":"2011","journal-title":"Inmunolog\u00eda"},{"issue":"8","key":"10.1016\/j.lfs.2024.123089_bb0395","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0400","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","article-title":"Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0405","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/stem.2393","article-title":"Sorensen, cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid-derived suppressor cell function and facilitates glioblastoma immune evasion","volume":"34","author":"Flavahan","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.lfs.2024.123089_bb0410","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3389\/fimmu.2020.00737","article-title":"The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment","volume":"11","author":"Mi","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2024.123089_bb0415","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/antiox9050374","article-title":"The double-faced role of nitric oxide and reactive oxygen species in solid tumors","volume":"9","author":"Mijatovi\u0107","year":"2020","journal-title":"Antioxidants"},{"issue":"8","key":"10.1016\/j.lfs.2024.123089_bb0420","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/0008-5472.CAN-07-6229","article-title":"Tumor escape mechanism governed by myeloid-derived suppressor cells","volume":"68","author":"Nagaraj","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123089_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585214","article-title":"Immunotherapy targeting myeloid-derived suppressor cells (MDSCs) in tumour microenvironment","volume":"11","author":"Gao","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0430","first-page":"1","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0435","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4049\/jimmunol.0804253","article-title":"Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells","volume":"183","author":"Hanson","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0440","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid-derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol. Rev."},{"issue":"20","key":"10.1016\/j.lfs.2024.123089_bb0445","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1007\/s00018-013-1286-4","article-title":"Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences","volume":"70","author":"Pillay","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.lfs.2024.123089_bb0450","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0455","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2024.123089_bb0460","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"1310","author":"Weber","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0465","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2024.123089_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.582106","article-title":"Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment","volume":"11","author":"Pearson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0475","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ebiom.2019.04.002","article-title":"Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma","volume":"43","author":"Han","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0480","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-065X.2011.01064.x","article-title":"The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation","volume":"244","author":"Steinberg","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2024.123089_bb0485","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/926321","article-title":"Targeting costimulatory molecules to improve antitumor immunity","volume":"2012","author":"Capece","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.lfs.2024.123089_bb0490","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fonc.2014.00275","article-title":"Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme","volume":"4","author":"Schuessler","year":"2014","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.lfs.2024.123089_bb0495","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-11-0992","article-title":"Is cytomegalovirus a therapeutic target in glioblastoma? Cytomegalovirus as tumor promoter and therapeutic target","volume":"17","author":"Sampson","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0500","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1514921","article-title":"The role of CMV in glioblastoma and implications for immunotherapeutic strategies","volume":"8","author":"Rahman","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lfs.2024.123089_bb0505","series-title":"Emerging and Re-emerging Viral Pathogens","first-page":"253","article-title":"Cytomegalovirus: an oncomodulator and therapeutic target in glioma management","author":"Fall","year":"2020"},{"key":"10.1016\/j.lfs.2024.123089_bb0510","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbrc.2020.01.148","article-title":"Indoleamine 2, 3-dioxygenase 1 is highly expressed in glioma stem cells","volume":"524","author":"Ozawa","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0515","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12032-022-01724-w","article-title":"The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies","volume":"39","author":"Hosseinalizadeh","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832263","article-title":"Indoleamine 2, 3-dioxygenase 1 mediates survival signals in chronic lymphocytic leukemia via kynurenine\/aryl hydrocarbon receptor-mediated MCL1 modulation","volume":"13","author":"Atene","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.977640","article-title":"Tryptophan 2, 3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: a meta-analysis and bioinformatics analysis","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0530","doi-asserted-by":"crossref","DOI":"10.1177\/11786469221138456","article-title":"Identification and characterization of a novel dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase","volume":"15","author":"Yoshioka","year":"2022","journal-title":"International Journal of Tryptophan Research"},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0535","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3390\/biomedicines10092292","article-title":"The interplay of tumor vessels and immune cells affects immunotherapy of glioblastoma","volume":"10","author":"Ghosh","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.lfs.2024.123089_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2022.823412","article-title":"Glioblastoma vasculature: from its critical role in tumor survival to relevant in vitro modelling","volume":"2","author":"Pacheco","year":"2022","journal-title":"Frontiers in Drug Delivery"},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0545","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0550","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0555","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10571-024-01488-z","article-title":"Extracellular matrix structure and interaction with immune cells in adult astrocytic tumors","volume":"44","author":"Di Vito","year":"2024","journal-title":"Cell. Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.lfs.2024.123089_bb0560","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/cancers16071276","article-title":"Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives","volume":"16","author":"Salvato","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.lfs.2024.123089_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-024-03675-9","article-title":"Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion","volume":"73","author":"Yu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0570","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PPO.0b013e3182431a73","article-title":"Immunotherapy for the treatment of glioblastoma","volume":"18","author":"Thomas","year":"2012","journal-title":"Cancer Journal (Sudbury, Mass.)"},{"issue":"4","key":"10.1016\/j.lfs.2024.123089_bb0575","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5306\/wjco.v14.i4.138","article-title":"Immunotherapy in glioblastoma treatment: current state and future prospects","volume":"14","author":"Pinheiro","year":"2023","journal-title":"World Journal of Clinical Oncology"},{"key":"10.1016\/j.lfs.2024.123089_bb0580","article-title":"Glioma-associated microglia\/macrophages (GAMs) in glioblastoma: immune function in the tumor microenvironment and implications for immunotherapy","volume":"14","author":"Lin","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2024.123089_bb0585","first-page":"1637","article-title":"Immunotherapy for glioblastoma: current progress and challenges","volume":"12","author":"Yu","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0590","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/ijms24032111","article-title":"Natural killer cell-based immunotherapy against glioblastoma","volume":"24","author":"Morimoto","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0595","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2353\/ajpath.2009.081034","article-title":"Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells","volume":"175","author":"Barcia","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0600","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44178-022-00021-w","article-title":"Peptide vaccine against glioblastoma: from bench to bedside","volume":"1","author":"Yang","year":"2022","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.lfs.2024.123089_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603911","article-title":"Current immunotherapies for glioblastoma multiforme","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2024.123089_bb0610","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.lfs.2024.123089_bb0615","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery","volume":"342","author":"Yan","year":"2022","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.lfs.2024.123089_bb0620","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1021\/acs.nanolett.9b04683","article-title":"Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy","volume":"20","author":"Liu","year":"2020","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0625","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy","volume":"11","author":"Gregory","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0630","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0635","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1038\/s41467-023-42365-5","article-title":"Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer","volume":"14","author":"Dong","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0640","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16219-x","article-title":"A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models","volume":"12","author":"Sadeghipour","year":"2022","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.lfs.2024.123089_bb0645","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2024.123089_bb0650","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.actbio.2019.01.020","article-title":"Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy","volume":"86","author":"Li","year":"2019","journal-title":"Acta Biomater."},{"issue":"10","key":"10.1016\/j.lfs.2024.123089_bb0655","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/pharmaceutics13101668","article-title":"Elucidating the innate immunological effects of mild magnetic hyperthermia on U87 human glioblastoma cells: an in vitro study","volume":"13","author":"Persano","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.lfs.2024.123089_bb0660","first-page":"1365","article-title":"High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme","volume":"13","author":"Kadiyala","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.lfs.2024.123089_bb0670","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/17425247.2013.758102","article-title":"Sustainable release of carmustine from biodegradable poly [(D, L)-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies","volume":"10","author":"Tseng","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2024.123089_bb0675","author":"National Library of Medicine (U.S.)"},{"issue":"9","key":"10.1016\/j.lfs.2024.123089_bb0680","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1021\/acsbiomaterials.3c00212","article-title":"Clinical theranostics trademark of exosome in glioblastoma metastasis","volume":"9","author":"Nag","year":"2023","journal-title":"ACS Biomater Sci. Eng."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0685","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.260","article-title":"Clinical impact of epithelial\u2013mesenchymal transition for cancer therapy","volume":"4","author":"Mukerjee","year":"2024","journal-title":"Clinical and Translational Discovery"},{"issue":"13","key":"10.1016\/j.lfs.2024.123089_bb0690","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-21-4370","article-title":"Epithelial\u2013mesenchymal plasticity in tumor immune evasion","volume":"82","author":"Mullins","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0695","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1021\/acsabm.3c00941","article-title":"Role of exosomes in epithelial\u2013mesenchymal transition","volume":"7","author":"Bhattacharya","year":"2023","journal-title":"ACS Appl. Bio Mater."},{"issue":"1","key":"10.1016\/j.lfs.2024.123089_bb0700","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.lfs.2024.123089_bb0705","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","article-title":"Applying artificial intelligence for cancer immunotherapy","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2024.123089_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1076883","article-title":"Advances in artificial intelligence to predict cancer immunotherapy efficacy","volume":"13","author":"Xie","year":"2023","journal-title":"Front Immunol"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524006799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524006799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:14:13Z","timestamp":1776096853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524006799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":142,"alternative-id":["S0024320524006799"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123089","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123089"}}